Home / Investors / Financial corner / Press releases / DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test